Cargando…

A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display

The explosion of SARS-CoV-2 infections in 2020 prompted a flurry of activity in vaccine development and exploration of various vaccine platforms, some well-established and some new. Phage-based vaccines were described previously, and we explored the possibility of using mycobacteriophages as a platf...

Descripción completa

Detalles Bibliográficos
Autores principales: Freeman, Krista G., Wetzel, Katherine S., Zhang, Yu, Zack, Kira M., Jacobs-Sera, Deborah, Walters, Sara M., Barbeau, Dominique J., McElroy, Anita K., Williams, John V., Hatfull, Graham F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704799/
https://www.ncbi.nlm.nih.gov/pubmed/34946016
http://dx.doi.org/10.3390/microorganisms9122414
_version_ 1784621794328576000
author Freeman, Krista G.
Wetzel, Katherine S.
Zhang, Yu
Zack, Kira M.
Jacobs-Sera, Deborah
Walters, Sara M.
Barbeau, Dominique J.
McElroy, Anita K.
Williams, John V.
Hatfull, Graham F.
author_facet Freeman, Krista G.
Wetzel, Katherine S.
Zhang, Yu
Zack, Kira M.
Jacobs-Sera, Deborah
Walters, Sara M.
Barbeau, Dominique J.
McElroy, Anita K.
Williams, John V.
Hatfull, Graham F.
author_sort Freeman, Krista G.
collection PubMed
description The explosion of SARS-CoV-2 infections in 2020 prompted a flurry of activity in vaccine development and exploration of various vaccine platforms, some well-established and some new. Phage-based vaccines were described previously, and we explored the possibility of using mycobacteriophages as a platform for displaying antigens of SARS-CoV-2 or other infectious agents. The potential advantages of using mycobacteriophages are that a large and diverse variety of them have been described and genomically characterized, engineering tools are available, and there is the capacity to display up to 700 antigen copies on a single particle approximately 100 nm in size. The phage body may itself be a good adjuvant, and the phages can be propagated easily, cheaply, and to high purity. Furthermore, the recent use of these phages therapeutically, including by intravenous administration, suggests an excellent safety profile, although efficacy can be restricted by neutralizing antibodies. We describe here the potent immunogenicity of mycobacteriophage Bxb1, and Bxb1 recombinants displaying SARS-CoV-2 Spike protein antigens.
format Online
Article
Text
id pubmed-8704799
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87047992021-12-25 A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display Freeman, Krista G. Wetzel, Katherine S. Zhang, Yu Zack, Kira M. Jacobs-Sera, Deborah Walters, Sara M. Barbeau, Dominique J. McElroy, Anita K. Williams, John V. Hatfull, Graham F. Microorganisms Article The explosion of SARS-CoV-2 infections in 2020 prompted a flurry of activity in vaccine development and exploration of various vaccine platforms, some well-established and some new. Phage-based vaccines were described previously, and we explored the possibility of using mycobacteriophages as a platform for displaying antigens of SARS-CoV-2 or other infectious agents. The potential advantages of using mycobacteriophages are that a large and diverse variety of them have been described and genomically characterized, engineering tools are available, and there is the capacity to display up to 700 antigen copies on a single particle approximately 100 nm in size. The phage body may itself be a good adjuvant, and the phages can be propagated easily, cheaply, and to high purity. Furthermore, the recent use of these phages therapeutically, including by intravenous administration, suggests an excellent safety profile, although efficacy can be restricted by neutralizing antibodies. We describe here the potent immunogenicity of mycobacteriophage Bxb1, and Bxb1 recombinants displaying SARS-CoV-2 Spike protein antigens. MDPI 2021-11-23 /pmc/articles/PMC8704799/ /pubmed/34946016 http://dx.doi.org/10.3390/microorganisms9122414 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Freeman, Krista G.
Wetzel, Katherine S.
Zhang, Yu
Zack, Kira M.
Jacobs-Sera, Deborah
Walters, Sara M.
Barbeau, Dominique J.
McElroy, Anita K.
Williams, John V.
Hatfull, Graham F.
A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display
title A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display
title_full A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display
title_fullStr A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display
title_full_unstemmed A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display
title_short A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display
title_sort mycobacteriophage-based vaccine platform: sars-cov-2 antigen expression and display
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704799/
https://www.ncbi.nlm.nih.gov/pubmed/34946016
http://dx.doi.org/10.3390/microorganisms9122414
work_keys_str_mv AT freemankristag amycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT wetzelkatherines amycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT zhangyu amycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT zackkiram amycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT jacobsseradeborah amycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT walterssaram amycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT barbeaudominiquej amycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT mcelroyanitak amycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT williamsjohnv amycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT hatfullgrahamf amycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT freemankristag mycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT wetzelkatherines mycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT zhangyu mycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT zackkiram mycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT jacobsseradeborah mycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT walterssaram mycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT barbeaudominiquej mycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT mcelroyanitak mycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT williamsjohnv mycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay
AT hatfullgrahamf mycobacteriophagebasedvaccineplatformsarscov2antigenexpressionanddisplay